logo
1 Safe-and-Steady Stock Worth Your Attention and 2 to Steer Clear Of

1 Safe-and-Steady Stock Worth Your Attention and 2 to Steer Clear Of

Yahoo13 hours ago

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Luckily for you, StockStory helps you navigate which companies are truly worth holding. That said, here is one low-volatility stock that could offer consistent gains and two that may not deliver the returns you need.
Rolling One-Year Beta: 0.15
Born out of a 2018 merger between Keurig Green Mountain and Dr Pepper Snapple, Keurig Dr Pepper (NASDAQ:KDP) is a consumer staples powerhouse boasting a portfolio of beverages including sodas, coffees, and juices.
Why Does KDP Worry Us?
Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 6.5% over the last three years was below our standards for the consumer staples sector
Expenses have increased as a percentage of revenue over the last year as its operating margin fell by 5.7 percentage points
ROIC of 5.7% reflects management's challenges in identifying attractive investment opportunities
Keurig Dr Pepper is trading at $32.63 per share, or 15.8x forward P/E. Check out our free in-depth research report to learn more about why KDP doesn't pass our bar.
Rolling One-Year Beta: 0.39
Named after the Massachusetts river where it was founded in 1947, Charles River Laboratories (NYSE:CRL) provides non-clinical drug development services, research models, and manufacturing support to pharmaceutical and biotechnology companies.
Why Are We Hesitant About CRL?
Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
Forecasted revenue decline of 2.6% for the upcoming 12 months implies demand will fall off a cliff
Eroding returns on capital from an already low base indicate that management's recent investments are destroying value
Charles River Laboratories's stock price of $140 implies a valuation ratio of 14.8x forward P/E. Read our free research report to see why you should think twice about including CRL in your portfolio, it's free.
Rolling One-Year Beta: 0.65
Selling excess inventory or overstocked items from other retailers, Ross Stores (NASDAQ:ROST) is an off-price concept that sells apparel and other goods at prices much lower than department stores.
Why Could ROST Be a Winner?
Offensive push to build new stores and attack its untapped market opportunities is backed by its same-store sales growth
Same-store sales growth averaged 3.5% over the past two years, showing it's bringing new and repeat shoppers into its stores
Stellar returns on capital showcase management's ability to surface highly profitable business ventures, and its returns are climbing as it finds even more attractive growth opportunities
At $142.24 per share, Ross Stores trades at 21.6x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it's free.
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

Yahoo

time24 minutes ago

  • Yahoo

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

Yahoo

time24 minutes ago

  • Yahoo

Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target

In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.

Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT
Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT

Yahoo

time24 minutes ago

  • Yahoo

Morgan Stanley Maintains Hold Rating on Snowflake (SNOW), Keeps $200 PT

Keith Weiss from Morgan Stanley maintained a Hold rating on Snowflake Inc. (NYSE:SNOW) on June 4, keeping the associated price target at $200.00. The analyst has an optimistic yet cautious outlook on the company. Weiss noted that its recent Investor Day showcased several key product innovations, particularly in AI integration across the company's offerings, which provides Snowflake Inc. (NYSE:SNOW) a strong foundation for future growth. A software engineer at work, surrounded by a wall of computer monitors connected to a 'Data Cloud' platform. However, the analyst also reasoned that the event failed to provide substantial financial updates, which led to uncertainty surrounding Snowflake Inc.'s (NYSE:SNOW) immediate financial trajectory. Weiss acknowledged that the company is continuously expanding its capabilities to handle unstructured, structured, and multi-modal data. Despite that, he opined that the stock may be priced high compared to its near-term growth prospects, which can be corroborated by its current valuation at 55 times the projected free cash flow for 2026. While Snowflake Inc. (NYSE:SNOW) has attractive long-term potential, Weiss justified the Hold rating by recommending that investors wait for a more favorable entry point before raising their investments. Snowflake Inc. (NYSE:SNOW) provides cloud data warehousing software. Its offerings include Data Cloud, and its platform supports a number of use cases, including data engineering, data warehousing, data sharing, data science, data application development, and more. While we acknowledge the potential of SNOW as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store